Joyce J. Lee left the role of Director at Phibro Animal Health Corp, effective April 15, 2026. As of November 6, 2026, Phibro Animal Health Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 14, 2026 to June 26, 2026, naming 1 departure (Form 8-K, April 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Phibro Animal Health Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Phibro Animal Health Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-14 to 2026-06-26. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Phibro Animal Health Corp files it.
Also on the record for Phibro Animal Health Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 19, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 3.9% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.1% of the class | 5%+ stakes | Source |
| May 22, 2026 | Stake report, Schedule 13D/A, by BFI Co., LLC | 48.2% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Barclays PLC | 1.27% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.06% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13D/A, by BFI Co., LLC | 48.3% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G, by FMR LLC | 10.5% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by Barclays PLC | 5.1% of the class | 5%+ stakes | Source |
| December 15, 2025 | Stake report, Schedule 13D/A, by BFI Co., LLC | 49.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Phibro Animal Health Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Phibro Animal Health Corp and the records around it.
Phibro Animal Health Corp elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
- Millennium Management LLC also filed stake reports on 121 other companies: StepStone Group Inc. (Nov 2026), Catalyst Acquisition Corp. (Nov 2026), RxSight, Inc. (Nov 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Phibro Animal Health Corp
Get an email when Phibro Animal Health Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Phibro Animal Health Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Phibro Animal Health Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Phibro Animal Health Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-26 | Reported | not named in the filing | 8-K, 2026-06-26 | ||
| 2026-04-14 | Out | Director | 2026-04-15 | 8-K, 2026-04-14 |
Who leads Phibro Animal Health Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Joyce J. Lee, departure reported, effective 2026-04-15 (filed 2026-04-14). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Phibro Animal Health Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Phibro Animal Health Corp, with the record behind each one.
Find candidates like Director at Phibro Animal Health CorpEvery change, in the filing's words
Reported
Employment Agreement Pursuant to the Employment Agreement, Mr. D. Bendheim will serve as the Chief Executive Officer and President of the Company starting on the Effective Date and ending on the date that such employment is terminated by either party pursuant to the termination provisions set forth in the Employment Agreement (such period, the "Term").
- During the Term, Mr. D. Bendheim will (i) receive a base salary at an annual rate of $850,000, (ii) be eligible to receive an annual discretionary bonus with a target bonus value of 50% of his base salary, (iii) be eligible to receive an annual award of time-vesting RSUs with a target value of approximately 50% of his base salary and (iv) receive the Initial RSUs.
- In the event Mr. D. Bendheim's employment terminates due to his death or "disability" (as defined in the Employment Agreement), Mr. D. Bendheim will be eligible to receive six months of continued base salary payments.
- Upon Mr. D. Bendheim's termination by the Company without Cause or by Mr. D. Bendheim for any reason, Mr. D. Bendheim will be eligible to receive up to 18 months of Company-subsidized COBRA coverage.
- The foregoing separation benefits are subject to Mr. D. Bendheim's (or his estate's, as applicable) execution and non-revocation of a release of claims against the Company and its affiliates.
- The Employment Agreement also entitled Mr. D. Bendheim to the Company's customary employee benefits and binds him to restrictive covenants regarding confidentiality, non-competition, non-solicitation, non-disparagement and the Company's ownership of intellectual property.
- RSU Award All of the Initial RSUs granted to Mr. D. Bendheim are subject to performance-based vesting.
Departing: Joyce J. Lee, Director, effective 2026-04-15
(a) On April 13, 2026, Ms. Joyce J. Lee, a member of the Board of the Directors (the "Board") of Phibro Animal Health Corporation (the "Company"), informed the Company that she intends to resign from her position as Director of the Company effective April 15, 2026.
- DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAN OFFICERS.
- Ms. Lee was a Class II Director of the Company.
- Ms. Lee's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for Phibro Animal Health Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.